Executive Director, DES Action USA Available for Comment on Pink Viagra & FDA Approval

Quick Hits: Transvaginal Mesh Pulled, New Weight Loss Drug & More

Advocacy group cites connection between experimental drug flibanserin and world’s first synthetic estrogen, cause of DES Tragedy

NEW YORK CITY, NY, June 15, 2015 – Suzanne Robotti, a DES Daughter and the Executive Director for DES Action USA, a nonprofit that advocates for DES-exposed individuals, is available to discuss concerns about the safety of flibanserin, the first FDA-approved drug for the treatment of female sexual dysfunction. In an 18-6 vote, a panel of Food and Drug Administration experts recommended allowing the experimental drug to be sold in the US as long as certain safety precautions are taken to minimize potential side effects such as low blood pressure, dizziness and fainting.

DES Action is the national organization for individuals exposed to diethylstilbestrol (DES) the world’s first synthetic estrogen, their families and health care providers. DES was prescribed to millions of pregnant women, primarily from 1938 – 1971, with the mistaken belief that the drug prevented miscarriage and ensured a healthy baby. It did neither and instead harmed the mothers who were prescribed it, the children born of those pregnancies and now possibly their grandchildren and beyond, leaving them with cancers, infertility and other health consequences, often called the DES Tragedy.

Among related topics, Robotti can discuss:
·       The crucial difference between flibanserin and Viagra, a hormone mixing into the central nervous system daily vs. an essentially mechanical and temporary action
·       The risk – benefit equation of taking flibanserin
·       The questionable role of gender equity in the FDA’s decision
·       The damages caused by the first synthetic hormone prescribed to women, DES

To schedule an interview with Suzanne Robotti or for additional information, please contact Julie Livingston at (347) 239-0249 or [email protected]

About DES Action USA
DES Action USA is the only national nonprofit organization for those who were exposed to the world’s first synthetic estrogen, diethylstilbestrol or DES. DES Action USA uses its website, newsletter and various social media platforms to provide education and advocacy for continued research into the health concerns of DES Mothers, DES Daughters, DES Sons and now DES Grandchildren. The organization works on spreading awareness about DES exposure to health care providers and the general public. Unlike many consumer health organizations, DES Action USA accepts no funding from drug companies. DES Action USA Group LLC is operated under MedShadow Foundation Inc, a 501c3 nonprofit. In 2014 received the designation of Top-Rated Nonprofits using Great Nonprofits.More information on www.desaction.org.

 


Did you find this article helpful?


Latest News

Prenatal Opioid Exposure Can Harm Children and Teens

Prenatal Opioid Exposure Can Harm Children and Teens

Most infants born with Prenatal Opioid Exposure (POE) look and seem completely unaffected – even those that go through withdrawal. A new meta-analysis shows that brain development and motor skills in children exposed to opioids in pregnancy lag behind other children significantly.

  • Advertisement